Professor Lietzan was recently a guest on “This Week in Health Law,” a commuting-length podcast that tackles thorny issues in health law and policy. She discussed her research on the relationship between drug innovation and incentives for innovation, and the conversation touched on large molecule drugs, biosimilars, data exclusivity and market exclusivity, patent protection, and her extensive empirical research on differences among different types of drugs and drug families. The podcast hosts blogged about the discussion on the widely read Harvard Law “Bill of Health” blog, noting that this is an “intensely complex area” for which they were “glad to have the benefit of a truly expert guide.”